Introduction
============

Adult-onset type II citrullinemia (CTLN2) is a urea cycle disease characterized by acute neuropsychological manifestations associated with hyperammonemia, such as disorientation, abnormal behavior, convulsions, and death due to brain edema ([@B1]). While recent studies have highlighted the importance of nutritional support, such as low carbohydrate diet, sodium pyruvate and arginine, for improving the prognosis of CTLN2, liver transplantation remains the only definitive therapy for CTLN2 ([@B2]-[@B6]). CTLN2 is caused by a dysfunction of citrin, which is a mitochondrial aspartate-glutamate carrier, one of the urea cycle enzymes, and encoded by the *SLC25A13* gene ([@B7]). Citrin dysfunction leads to a rise in the cytosolic NADH level in the liver, together with an over-production of fatty acids and the suppression of the fatty acid metabolism ([@B8]-[@B10]). Since the carbohydrate metabolism increases the cytosolic NADH levels in the liver, carbohydrate-rich foods in CTLN2 patients could worsen the metabolic state in the hepatocytes ([@B3]). One of the clinical features of CTLN2, explained by the abovementioned pathology, is food preferences for protein- and fat-rich foods, such as peanuts, butter and cheese, and the avoidance of carbohydrate-rich foods, such as rice, sweets and alcohol ([@B9]). Although the body mass index (BMI) is \<20 kg/m^2^ in 90% of CTLN2 patients, one of the pathological features of CTLN2 patients is the presence of a fatty liver ([@B10],[@B11]).

A genetic analysis \[mutations in the *SLC25A13* gene ([@B7])\] is essential in the diagnosis of CTLN2 (prepared by the research group and approved by the academic society), whereas hepatic steatosis is not necessary for a definitive diagnosis. In fact, previous studies that included liver biopsy in the diagnostic workup of CTLN2 found hepatocyte steatosis in almost all CTLN2 patients, and these patients subsequently developed nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) ([@B5],[@B12]-[@B15]).

In this report, we describe a rare case of a CTLN2 patient with a histopathologically confirmed lack of hepatocyte steatosis who was assessed by 7-year interval paired biopsies and treated successfully with a low carbohydrate diet.

Liver histopathology
--------------------

We obtained written informed consent from the patient before performing a ultrasonography-guided percutaneous liver biopsy and the use of genomic DNA data. Liver specimens were obtained with a 16-gauge core tissue biopsy needle (Bard Peripheral Vascular, Tempe, USA). The specimen was fixed in 10% formalin and the prepared sections were stained with Hematoxylin-Eosin (H&E) and Masson trichrome after diastase digestion. Four pathologists (authors, KK, FK, TF, and TF), who were blinded to the clinical findings, evaluated each specimen, and the final diagnosis was made by consensus. An adequate liver biopsy sample was defined as a specimen longer than 1.5 cm and/or containing more than 11 portal tracts. Steatosis grade 0, 1, 2, and 3, corresponded to steatosis of \<5%, ≥5 to \<33%, ≥33 to \<66%, and ≥66%, respectively. Lobular inflammation with no foci, \<2 foci, 2-4 foci, and ≥4 foci per 200× field was scored as 0, 1, 2, and 3, respectively. Hepatocyte ballooning of none, few, and many cells was scored as 0, 1, and 2, respectively. The fibrosis stage of none, zone 3 peri-sinusoidal fibrosis (stage 1), zone 3 peri-sinusoidal fibrosis with portal fibrosis (stage 2), zone 3 peri-sinusoidal fibrosis and portal fibrosis with bridging fibrosis (stage 3), and cirrhosis (stage 4) was scored as 0, 1, 2, 3, and 4, respectively ([@B16],[@B17]).

Case Report
===========

A 74-year-old woman was admitted to a local hospital in May 2009 for an acute impairment of consciousness and urinary incontinence. On admission, a clinical examination showed flapping tremor and blood tests showed hyperammonemia (NH~3~: 151 μg/dL), though imaging studies were negative for chronic liver disease, porto-systemic shunt, and fatty liver. The brain magnetic resonance imaging (MRI) findings were normal, and there were no clinical or imaging abnormalities that could explain the disturbance of consciousness (data not shown). She was diagnosed to have hepatic encephalopathy and was treated with oral lactulose and a low-weight protein diet. Ultrasonography-guided percutaneous liver biopsy (performed in December 2009), showed no evidence of liver cirrhosis, grade 0 steatosis (3%), and fibrosis stage 1 ([Fig. 1a and b](#g001){ref-type="fig"}). While her consciousness improved temporarily, the frequency of encephalopathy attacks with hyperammonemia increased. She was referred to our hospital in October 2016 for further investigation. Chronic hepatitis and fatty liver changes were ruled out based on the results of blood tests and contrast-enhanced CT and proton density fat fraction (PDFF) using MRI ([@B18]) ([Fig. 2](#g002){ref-type="fig"}). Ultrasonography-guided percutaneous liver biopsy showed grade 0 steatosis (\<1%), and fibrosis stage 1, but the absence of Mallory body or hepatocyte ballooning ([Fig. 1c and d](#g001){ref-type="fig"}). She reported drinking alcohol socially only at less than 20 g per day, and her food preference was protein- and fat-rich foods, such as peanuts and butter since childhood. No comorbidity was found, such as diabetes or hypertension, which can be risk factors for hepatic steatosis. A serum amino acid analysis showed high levels of serum citrulline and arginine, while a DNA analysis demonstrated compound heterozygosity with \[II\]c.1018+1G\>A and \[IV\] c.674C\>A mutations in the *SLC25A13* gene ([@B7]). The final diagnosis was CTLN2 based on the above findings. A low-carbohydrate diet (protein: fat: carbohydrate ratio= 20:40:40%) was started. This was followed by a decrease in the frequency of encephalopathy attacks with hyperammonemia ([Table](#t001){ref-type="table"}).

![Histopathological findings. (a) Grade 0 steatosis (3%) (Hematoxylin and Eosin (H&E) staining, ×200). (b) Grade 1 fibrosis (Masson trichrome ×80). (c) Grade 0 steatosis (\<1%). Note the absence of Mallory body and hepatocyte ballooning (H&E staining, ×200). (d) Grade 1 fibrosis (Masson trichrome ×80).](1349-7235-58-1891-g001){#g001}

![Imaging findings. (a) Contrast-enhanced CT shows a normal liver, (b) MRI-PDFF shows 2.4% hepatic steatosis.](1349-7235-58-1891-g002){#g002}

###### 

Clinicopathological Data.

  Age (years)                     67        74                                      
  ------------------------------- --------- -------------- --------- -------------- ---------
  Ammonia (6-51 μg/dL)^§^         151       64             132       34             39
  Citrulline (20-48 nmol/mL)^§^   \-        419.5          865.3     501.8          336.5
  Arginine (70-128 nmol/mL)^§^    \-        268.2          358.1     348.3          280.2
  Threonine (39-74 nmol/mL)^§^    \-        108.9          142.8     129.5          172.3
  Serine (77-150 nmol/mL)^§^      \-        50.1           57.1      47.8           60.1
  Threonine-to-serine ratio       \-        2.17           2.5       2.71           2.87
  AST / ALT (IU/L)                39 / 38   40 / 39        23 / 16   23 / 17        24 / 29
  Albumin (g/dL)                  3.2       3.2            3.5       3.5            3.6
  Platelet (×10^4^/μL)            32.5      32.5           25.7      25.4           25.5
  Total cholesterol (mg/dL)       \-        \-             177       \-             168
  Triglyceride (mg/dL)            \-        \-             49        \-             51
  Magnetic Resonance Imaging                NA                       Normal liver   
  Ultrasonography                           Normal liver             Normal liver   
  Liver histopathology (date)               2009                     2016           
  Steatosis (Grade /%)                      0 /3%                    0 /\<1%        
  Ballooning                                2                        0              
  Lobular inflammation                      2                        1              
  Fibrosis stage                            1                        1              
  Mallory Body                              \+                       −              
  Glycogen nucleus                          \+                       \+             

\*another hospital,^¶^our hospital,^§^normal range

NA: not available, AST: aspartate aminotransferase, ALT: alanine aminotransferase

Discussion
==========

CTLN2 patients show a unique dietary preference for protein- and fat-rich foods, such as beans and peanuts, and often avoid carbohydrate-rich foods, such as rice and alcohol, as a compensatory response to hepatocyte metabolic dysfunction. Accordingly, hepatocyte metabolic dysfunction worsens when CTLN2 patients are erroneously diagnosed as hepatic encephalopathy and placed on low-weight protein diet. This is the first case demonstrating that hepatic encephalopathy could be worsened by carbohydrate-rich food even when CTLN2 is not associated with hepatocyte steatosis. Although almost all CTLN2 cases dislike the consumption of alcohol since it rich in carbohydrates and causes fatty liver changes, many CTLN2 patients could be wrongfully misdiagnosed as NASH. Thus, even in patients with acute neuropsychological disorders associated with hyperammonemia, who have a low BMI and are negative for hepatocyte steatosis, an analysis of the dietary habits and serum amino acid levels may help in establishing the diagnosis. Unfortunately, a serum pancreatic secretory trypsin inhibitor (PSTI) gene analysis was not available at the time of the clinical management. In this regard, high serum PSTI levels have been reported to be a useful diagnostic marker for CTLN2 ([@B19]).

Saheki et al. ([@B1],[@B9]) reported that the prevalence of CTLN2 in Japan was approximately 1/100,000- 230,000 persons, while the number of male CTLN2 patients is 2.4 times higher than that of females. In this case report, although the patient had the typical dietary habit of CTLN2, no symptoms were noted until she was 67 years old without hepatocyte steatosis, thus representing a long-term survival without liver transplantation. While we did not analyze the mechanism of the latent appearance of overt clinical features of CTLN2 in our patient, it is possible that such a phenotype is more likely to be seen in females than males, based on a possible gender difference in resistance to the onset of CTLN2 and the suppression of fat deposition in the liver. In this regard, Inui et al. ([@B20]) also reported an 8-year-old girl with CTLN2 who presented with chronic hepatitis without hepatic steatosis.

Komatsu et al. ([@B13]) reported that the expression of peroxisome proliferator activated receptor α (PPARα), one of the master regulators of the hepatic lipid metabolism, is down-regulated in CTLN2 patients and inversely correlated with the severity of hepatocyte steatosis. Furthermore, four separate groups who studied 35 cases of CTLN2, including a liver biopsy, and all demonstrated the presence of mild to severe hepatocyte steatosis ([@B12]-[@B15]). To our knowledge, however, our case is the first without hepatocyte steatosis, as confirmed twice by histopathological examination based on the findings of 7-year interval paired biopsies. We cannot, however, exclude the possibility, that this heterogeneity is due to sampling variability by the liver biopsy. In this report, the histopathological findings closely correlated with those of imaging studies, such as MRI and ultrasonography. Furthermore, the findings were confirmed in the biopsies obtained 7-year apart, which both showed a lack of fatty liver changes. Accordingly, we believe that the histopathological assessment was reasonable.

In conclusion, we herein described the first known case of CTLN2 which was free of hepatocyte steatosis.
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